Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | IDH2 | P48735 | 3/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.30 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.30 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5176229 | 0.76 | CHEK1 (0.39) | CHEK1CDK1GLAKCNJ5KCNJ3 | |
| SCHEMBL5174652 | 0.72 | CHEK1 (0.39) | CHEK1CDK1GLA | |
| SCHEMBL5171755 | 0.70 | NUDT1 (0.41) | CDK1KDM4EALDH1A1HPGDCYP1A2 | |
| SCHEMBL33651 | 0.68 | MAPT (0.41) | ALDH1A1HPGDCYP1A2IDH2 | |
| SCHEMBL5172906 | 0.68 | PKM (0.38) | CHEK1CDK1KDM4EALDH1A1IDH2 | |
| SCHEMBL3919119 | 0.66 | ALDH1A1 (0.41) | ALDH1A1HPGDCYP1A2 | |
| SCHEMBL3937332 | 0.66 | EGFR (0.41) | CHEK1CDK1CYP1A2GLA | |
| SCHEMBL30716707 | 0.66 | EGFR (0.41) | CHEK1CDK1CYP1A2GLA | |
| SCHEMBL26626445 | 0.66 | EGFR (0.41) | CHEK1CDK1CYP1A2GLA | |
| SCHEMBL7897990 | 0.66 | EGFR (0.41) | CHEK1CDK1CYP1A2GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050198745-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | PROCTER & GAMBLE COMPANY, THE | 2005-09-15 | — | — | US | claimed |
| US-7297168-B2 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2007-11-20 | — | — | US | disclosed |
| US-20050198745-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | PROCTER & GAMBLE COMPANY, THE | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050198745-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | KRT18, CKMT1A; CKMT1B, CYB5R3 | CHEK1 1300/4885CDK1 1402/4885KDM4E 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.